Evidence map›Paper›PMID 42827668›Full record

ArticleAvicenna journal of medical biotechnology

miR-103/107-Mediated Suppression of NKILA Enhances Oncogenic Behaviors in Human Lung Cancer Cells.

Davood Jafari, Hossein Naghiloo, Seyyed Shamsadin Athari, Farshid Noorbakhsh, Nima Rezaei

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Avicenna journal of medical biotechnology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Davood JafariDepartment of Immunology, School of Medicine, Zanjan University of Medical Sciences, Zanjan, Iran.
Hossein NaghilooStudent Research Committee, School of Medicine, Zanjan University of Medical Sciences, Zanjan, Iran.
Seyyed Shamsadin AthariDepartment of Immunology, School of Medicine, Zanjan University of Medical Sciences, Zanjan, Iran.
Farshid NoorbakhshDepartment of Immunology, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran.
Nima RezaeiDepartment of Immunology, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Lung cancer remains a major global health burden, and conventional therapies often fail to meet clinical needs. Although non-coding RNAs are increasingly recognized as key regulators in cancer, the role of NKILA and its modulation by the miR-103/107 cluster in lung cancer growth and metastasis is not fully characterized. This study investigates the impact of the NKILA-miR-103/107 axis on lung cancer progression and metastatic behavior. Methods: To suppress miR-103 and miR-107 activity in the human lung cancer cell line A549, specific LNA-based inhibitors were introduced into the cells. Following Results: In lung cancer A549 cells, suppression of miR-103/107 using LNA inhibitors led to a marked elevation in NKILA transcript levels. Functional assays showed that miR-103/107 inhibition was associated with a significant decrease in A549 cell viability (p=0.0041) and a pronounced reduction in invasive capacity (p=0.001). Conclusion: In this

Indexed as

Cell proliferationCell survivalGlobal healthLung neoplasmsMicroRNAsReal-time polymerase chain reactionTransfection

Identifiers

PMID42827668
PMCPMC13631537

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.